For the quarter ending 2025-09-30, SION had $9,846K increase in cash & cash equivalents over the period. -$15,317K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,278 | -34,550 |
| Stock-based compensation expense | 3,306 | 4,934 |
| Non-cash operating lease expense | 490 | 981 |
| Amortization of discount on marketable securities | 836 | 1,863 |
| Non-cash expense related to ipr&d acquisition | 0 | - |
| Depreciation expense | 189 | 306 |
| Prepaid expenses and other current assets | -177 | 720 |
| Accounts payable | 567 | -272 |
| Accrued expenses and other current liabilities | 1,684 | -2,201 |
| Operating lease liabilities | -529 | -1,056 |
| Other assets | 0 | 0 |
| Net cash used in operating activities | -15,230 | -34,441 |
| Purchases of property and equipment | 87 | 86 |
| Purchases of marketable securities | 54,136 | 228,011 |
| Maturities of marketable securities | 77,325 | 63,658 |
| Net cash used in investing activities | 23,102 | -164,439 |
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | 0 | 202,071 |
| Proceeds from issuance of series c convertible preferred stock, net of issuance costs | 0 | 0 |
| Payment of deferred offering costs | 0 | - |
| Exercise of common stock options | 1,974 | 6 |
| Net cash provided by financing activities | 1,974 | 202,077 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 9,846 | 3,197 |
| Cash and cash equivalents at beginning of period | 38,750 | - |
| Cash and cash equivalents at end of period | 51,793 | - |
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)